FDA approves Merck’s Recarbrio for treating ventilator- and hospital-associated pneumonia June 5, 2020 By Lee Landenberger No Comments The FDA has approved Recarbrio (imipenem-cilastatin and relebactam), from Merck & Co. Inc., of Kenilworth, N.J., to treat adults with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).Read More